Literature DB >> 11228384

Potency of clinical group B streptococcal conjugate vaccines.

L C Paoletti1.   

Abstract

The potency of clinical group B streptococcal (GBS) capsular polysaccharide-protein conjugate vaccines has been assessed with use of a mouse maternal vaccination-neonatal pup challenge model of GBS disease. Two of the three conjugated GBS vaccines bottled as liquid preparations showed a potency reduction from 100% to < or = 50% in 3 years; whereas all six vaccines bottled as lyophilized preparations with sucrose excipient exhibited no loss of potency during the same span of time. A reconstituted GBS conjugate vaccine remained potent and antigenically intact after 31 days' storage at 2-8 degrees C. These data suggest that lyophilization in the presence of sucrose extends the potency of GBS conjugate vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228384     DOI: 10.1016/s0264-410x(00)00437-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.

Authors:  Ravin Seepersaud; Sean B Hanniffy; Peter Mayne; Phil Sizer; Richard Le Page; Jerry M Wells
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Identification of a universal Group B streptococcus vaccine by multiple genome screen.

Authors:  Domenico Maione; Immaculada Margarit; Cira D Rinaudo; Vega Masignani; Marirosa Mora; Maria Scarselli; Hervé Tettelin; Cecilia Brettoni; Emilia T Iacobini; Roberto Rosini; Nunzio D'Agostino; Lisa Miorin; Scilla Buccato; Massimo Mariani; Giuliano Galli; Renzo Nogarotto; Vincenzo Nardi-Dei; Vincenzo Nardi Dei; Filipo Vegni; Claire Fraser; Giuseppe Mancuso; Giuseppe Teti; Lawrence C Madoff; Lawrence C Paoletti; Rino Rappuoli; Dennis L Kasper; John L Telford; Guido Grandi
Journal:  Science       Date:  2005-07-01       Impact factor: 47.728

Review 3.  Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.

Authors:  Michael S Bronze; James B Dale
Journal:  Am J Med Sci       Date:  2010-09       Impact factor: 2.378

4.  Oxygen regulates invasiveness and virulence of group B streptococcus.

Authors:  Atul K Johri; Joahnna Padilla; Gennady Malin; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

5.  Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits.

Authors:  Lawrence C Paoletti; Hilde-Kari Guttormsen; Mildred S Christian; Alan M Hoberman; Pamela McInnes
Journal:  Hum Vaccin       Date:  2008-11-21

6.  Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching.

Authors:  Hilde-Kari Guttormsen; Lawrence C Paoletti; Keith G Mansfield; Wojcieck Jachymek; Harold J Jennings; Dennis L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-31       Impact factor: 11.205

7.  A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity.

Authors:  Joan E Smallshaw; Ellen S Vitetta
Journal:  Vaccine       Date:  2010-01-12       Impact factor: 3.641

8.  Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein.

Authors:  Denis Martin; Stéphane Rioux; Edith Gagnon; Martine Boyer; Josée Hamel; Nathalie Charland; Bernard R Brodeur
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.